Literature DB >> 18155828

The mutations and potential targets of the forkhead transcription factor FOXL2.

L Moumné1, F Batista, B A Benayoun, J Nallathambi, M Fellous, P Sundaresan, R A Veitia.   

Abstract

Mutations of FOXL2, a gene encoding a forkhead transcription factor, have been shown to cause the blepharophimosis-ptosis-epicanthus inversus syndrome (BPES). This genetic disorder is characterized by eyelid and mild craniofacial abnormalities that can appear associated with premature ovarian failure. FOXL2 is one of the earliest ovarian markers and it offers, along with its targets, an excellent model to study ovarian development and function in normal and pathological conditions. In this review we summarize recent data concerning FOXL2, its mutations and its potential targets. Indeed, many mutations have been described in the coding sequence of FOXL2. Among them, polyalanine expansions and premature nonsense mutations have been shown to induce protein aggregation. In the context of the ovary, FOXL2 has been suggested to be involved in the regulation of cholesterol and steroid metabolism, apoptosis, reactive oxygen species detoxification and inflammation processes. The elucidation of the impact of FOXL2 mutations on its function will allow a better understanding of the pathogenic mechanisms underlying the BPES phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18155828     DOI: 10.1016/j.mce.2007.11.006

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  18 in total

1.  Revisiting reproduction: What a difference a gene makes.

Authors:  Bruce D Murphy
Journal:  Nat Med       Date:  2010-05       Impact factor: 53.440

2.  FOXO1/3 and PTEN Depletion in Granulosa Cells Promotes Ovarian Granulosa Cell Tumor Development.

Authors:  Zhilin Liu; Yi A Ren; Stephanie A Pangas; Jaye Adams; Wei Zhou; Diego H Castrillon; Dagmar Wilhelm; JoAnne S Richards
Journal:  Mol Endocrinol       Date:  2015-06-10

Review 3.  The ovary: basic biology and clinical implications.

Authors:  Joanne S Richards; Stephanie A Pangas
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

Review 4.  New insights into ovarian function.

Authors:  Joanne S Richards; Stephanie A Pangas
Journal:  Handb Exp Pharmacol       Date:  2010

5.  Conditional deletion of the retinoblastoma (Rb) gene in ovarian granulosa cells leads to premature ovarian failure.

Authors:  Claudia Andreu-Vieyra; Ruihong Chen; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2008-07-03

6.  FSH and FOXO1 regulate genes in the sterol/steroid and lipid biosynthetic pathways in granulosa cells.

Authors:  Zhilin Liu; Michael D Rudd; Inmaculata Hernandez-Gonzalez; Ignacio Gonzalez-Robayna; Heng-Yu Fan; Anthony J Zeleznik; JoAnne S Richards
Journal:  Mol Endocrinol       Date:  2009-02-05

7.  The transcriptional targets of mutant FOXL2 in granulosa cell tumours.

Authors:  Roseanne Rosario; Hiromitsu Araki; Cristin G Print; Andrew N Shelling
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

8.  MuSiC: identifying mutational significance in cancer genomes.

Authors:  Nathan D Dees; Qunyuan Zhang; Cyriac Kandoth; Michael C Wendl; William Schierding; Daniel C Koboldt; Thomas B Mooney; Matthew B Callaway; David Dooling; Elaine R Mardis; Richard K Wilson; Li Ding
Journal:  Genome Res       Date:  2012-07-03       Impact factor: 9.043

9.  Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis.

Authors:  J S Richards; H-Y Fan; Z Liu; M Tsoi; M-N Laguë; A Boyer; D Boerboom
Journal:  Oncogene       Date:  2011-08-22       Impact factor: 9.867

10.  Functional exploration of the adult ovarian granulosa cell tumor-associated somatic FOXL2 mutation p.Cys134Trp (c.402C>G).

Authors:  Bérénice A Benayoun; Sandrine Caburet; Aurélie Dipietromaria; Adrien Georges; Barbara D'Haene; P J Eswari Pandaranayaka; David L'Hôte; Anne-Laure Todeschini; Sankaran Krishnaswamy; Marc Fellous; Elfride De Baere; Reiner A Veitia
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.